%2520white_edited.png)
In clinical trials, the most common adverse reactions reported by children aged 6 months to under 2 years who received any dose of the vaccine included agitation, decreased appetite, injection site tenderness, injection site redness, fever and injection site swelling, the FDA said.
The Food and Drug Administration of the Ministry of Health phone database and Welfare announced today (1) that the expert meeting has approved the Pfizer BNT (Pfizer-BioNTech) vaccine for children aged 6 months to 4 years old. Doses should be administered at least 21 days apart, and a third dose should be administered at least 8 weeks after the second dose. The exact opening date of vaccination will be announced by the Central Epidemic Epidemic Command Center. The Food and Drug Administration issued a press release this morning , noting that an expert meeting was held on July 29 to discuss whether to approve the Pfizer BNT vaccine for active immunization of children 6 months to 4 years of age to prevent COVID-19 (severe disease).
Special Infectious Pneumonia, New Coronary Pneumonia, Wuhan Pneumonia). According to the Food and Drug Administration, after reviewing the results of a Phase I, II, and III clinical trial of Pfizer’s BNT vaccine in children aged 6 months to 4 years, the test results showed that the experimental group of children aged 6 months to 4 years old was induced. The immunogenicity results of neutralizing antibodies were non-inferior to those of the adolescent and adult trial groups; in terms of safety, compared with other age groups, there were no new safety concerns.